|
Press Releases |
|
 |
|
Friday, August 30, 2024 |
|
華領醫藥公佈2024年中期業績 |
全球首創新藥雙功能葡萄糖激酶激活劑(GKA)多格列艾汀(商品名:華堂寧®)于2023年底成功納入《國家基本醫療保險、工傷保險和生育保險藥品目錄》(“國家醫保藥品目錄”)。華領醫藥與商業化合作夥伴拜耳以及80家一級經銷商共同推動多格列艾汀的商業化,開始進入中國31個省級醫藥市場。 more info >> |
|
华领医药公布2024年中期业绩 |
华领医药(“公司”,香港联交所股份代号:2552)宣布公司及其附属公司截至2024年6月30日止,6个月(“报告期”)未经审核的综合业绩,以及公司上半年业务进展和未来业务展望。 more info >> |
|
Friday, August 25, 2023 |
|
华领医药公布2023年中期业绩 |
-- 全球首创新药葡萄糖激酶激活剂(GKA)多格列艾汀(商品名:华堂宁®)于2022年9月在中国获批上市。 more info >> |
|
華領醫藥公佈2023年中期業績 |
-- 全球首創新藥葡萄糖激酶激活劑(GKA)多格列艾汀(商品名:華堂寧®)於2022年9月在中國獲批上市。 more info >> |
|
Hua Medicine Announces 2023 Interim Results |
First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
Monday, October 10, 2022 |
|
华领医药全球首创新药葡萄糖激酶激活剂华堂宁(R)获批上市 有望拓展中国2型糖尿病治疗新格局 |
华领医药(「公司」,香港联交所股份代号:2552.HK)今天宣布,公司研发的全球首创(first-in-class)新药葡萄糖激酶激活剂(GKA)华堂宁®(多格列艾汀片,dorzagliatin,HMS5552)已于10月8日获得中国国家药品监督管理局(NMPA)的上市批准。 more info >> |
|
華領醫藥全球首創新藥葡萄糖激酶激活劑華堂寧(R)獲批上市 有望拓展中國2型糖尿病治療新格局 |
華領醫藥(「公司」,香港聯交所股份代號:2552.HK)今天宣佈,公司研發的全球首創(first-in-class)新藥葡萄糖激酶激活劑(GKA)華堂寧®(多格列艾汀片,dorzagliatin,HMS5552)已於10月8日獲得中國國家藥品監督管理局(NMPA)的上市批准。 more info >> |
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
Tuesday, June 7, 2022 |
|
華領醫藥在2022ADA科學年會公佈多格列艾汀能夠明顯改善2型糖尿病患者和GCK-MODY患者的胰島素早相分泌和葡萄糖敏感性 |
華領醫藥(「公司」,香港聯交所股份代號:2552.HK)今天宣佈,在第82屆美國糖尿病協會(ADA)科學年會上,公司展示了其全球首創新藥葡萄糖激酶啟動劑(GKA)多格列艾汀(dorzagliatin)的多項臨床研究成果。 more info >> |
|
华领医药在2022ADA科学年会公布多格列艾汀能够明显改善2型糖尿病患者和GCK-MODY患者的胰岛素早相分泌和葡萄糖敏感性 |
华领医药(「公司」,香港联交所股份代号:2552.HK)今天宣布,在第82届美国糖尿病协会(ADA)科学年会上,公司展示了其全球首创新药葡萄糖激酶激活剂(GKA)多格列艾汀(dorzagliatin)的多项临床研究成果。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Singapore's Digital Finance Model in Focus at the BFSI IT Summit - Singapore 2025
Aug 11, 2025 18:26 HKT/SGT
|
|
|
WRC 2025: Shoucheng Showcases Full Robotics Value Chain
Aug 11, 2025 16:27 HKT/SGT
|
|
|
Intellifusion Submits an Application to List on the Hong Kong Stock Exchange: A National Breakthrough in AI Inference Chips
Aug 11, 2025 16:25 HKT/SGT
|
|
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan
Aug 11, 2025 16:25 HKT/SGT
|
|
|
Campaign to promote Hong Kong's advantages in professional services in Vietnam
Aug 11, 2025 16:03: JST
|
|
|
Campaign to promote Hong Kong's advantages in professional services in Vietnam
Aug 11, 2025 15:03 HKT/SGT
|
|
|
31 Concept to Debut Patent-Pending Technology at ISS Asia 2025 in Singapore
Aug 11, 2025 13:13 HKT/SGT
|
|
|
31 Concept將在2025年新加坡ISS Asia首度發佈其申請專利的新技術
Aug 11, 2025 13:13 HKT/SGT
|
|
|
Qube Celebrates 20 Years of Business Events Impact with Industry Recognition and Vision for the Future
Aug 11, 2025 12:03 HKT/SGT
|
|
|
TransNusa Focuses on Organic Growth to Strengthen Network Connectivity in China
Aug 11, 2025 11:00 HKT/SGT
|
|
|
沙烏地電力公司2025年第二季淨利成長22%
Aug 11, 2025 11:00 HKT/SGT
|
|
|
Cryofocus Medtech Achieves Record Interim Results with 162% Revenue Surge Driven by Respiratory Intervention Products
Aug 11, 2025 10:41 HKT/SGT
|
|
|
康灃生物中期業績創紀錄 呼吸介入產品驅動收入激增162%
Aug 11, 2025 10:41 HKT/SGT
|
|
|
康沣生物中期业绩创纪录 呼吸介入产品驱动收入激增162%
Aug 11, 2025 10:41 HKT/SGT
|
|
|
Shoucheng-Backed Data Center REITs Surge on Market Debut
Aug 11, 2025 09:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|